“Three U.S. senators ask Mylan for EpiPen military reimbursements” plus 9 more Reuters: Health News |
- Three U.S. senators ask Mylan for EpiPen military reimbursements
- Bayer applies for Regorafenib authorization to treat liver cancer
- Roche says flexible pricing ready for cancer, not MS drugs
- Stanford uses CRISPR to correct sickle cell, human trials planned
- Childhood cancer survivors have lasting health problems even with newer treatments
- British American Tobacco to test tobacco e-cigarette in Japan
- Anesthesia before age 4 may have small effect on academics later
- Roche advances skin cancer trials as part of combination therapy strategy
- 'Lazy mosquitoes' mean more women than men get chikungunya: scientists
- Monthly cost of providing key drugs could be $1-2 per person: experts
| Three U.S. senators ask Mylan for EpiPen military reimbursements Posted: 07 Nov 2016 02:34 PM PST (Reuters) - Three members of the U.S. Senate Judiciary Committee, ahead of a planned hearing late this month, said Mylan NV appears to have greatly overcharged the military for its lifesaving allergy treatment EpiPen and asked the pharmaceutical company when it plans to reimburse the Department of Defense. |
| Bayer applies for Regorafenib authorization to treat liver cancer Posted: 07 Nov 2016 01:00 AM PST FRANKFURT (Reuters) - German drugmaker Bayer on Monday said it submitted an application to have its cancer drug Regorafenib approved for the second-line treatment of liver cancer patients following successful clinical trials. |
| Roche says flexible pricing ready for cancer, not MS drugs Posted: 07 Nov 2016 03:12 PM PST ZURICH (Reuters) - The spotlight on finding a cancer cure has spurred improvements in systems to collect and analyze oncology data, but efforts to track patients with other diseases lag behind, Roche pricing head Jens Grueger said. |
| Stanford uses CRISPR to correct sickle cell, human trials planned Posted: 07 Nov 2016 04:03 PM PST CHICAGO (Reuters) - Scientists at Stanford University School of Medicine have used the CRISPR gene editing tool to repair the gene that causes sickle cell disease in stem cells from diseased patients, paving the way for a potential cure for the disease, which affects up to 5 million people globally. |
| Childhood cancer survivors have lasting health problems even with newer treatments Posted: 07 Nov 2016 04:50 PM PST (Reuters Health) - Despite advances that have made treatments safer and more effective, childhood cancer survivors don't appear to have experienced gains in long-term health outcomes, a new study suggests. |
| British American Tobacco to test tobacco e-cigarette in Japan Posted: 08 Nov 2016 12:07 AM PST TOKYO/LONDON (Reuters) - British American Tobacco PLC (BAT) plans to test a new tobacco-based cigarette alternative in Japan next month, it said on Tuesday, taking aim at Philip Morris International Inc's popular iQOS and Japan Tobacco Inc's Ploom Tech. |
| Anesthesia before age 4 may have small effect on academics later Posted: 07 Nov 2016 10:36 AM PST (Reuters Health) - Kids who are exposed to surgical anesthesia before age four tend to have slightly lower school grades at age 16 compared to other kids, but the difference is very small and shouldn't discourage parents from proceeding with necessary surgeries, researchers say. |
| Roche advances skin cancer trials as part of combination therapy strategy Posted: 07 Nov 2016 01:06 AM PST ZURICH (Reuters) - Roche is pressing ahead with two skin cancer trials that combine its immunotherapy Tecentriq with other drugs after early data showed the treatments were well-tolerated and effective in a small number of patients, the company said Monday. |
| 'Lazy mosquitoes' mean more women than men get chikungunya: scientists Posted: 07 Nov 2016 05:20 PM PST LONDON (Thomson Reuters Foundation) - "Lazy mosquitoes" are the reason why women, who tend to spend more time at home than men, are more likely to be infected by chikungunya, a painful mosquito-borne viral disease which spreads the same way as Zika, researchers said on Monday. |
| Monthly cost of providing key drugs could be $1-2 per person: experts Posted: 07 Nov 2016 05:22 PM PST LONDON (Thomson Reuters Foundation) - Essential medicines could be provided for as little as $1-$2 a month per person in developing countries, experts said on Monday as they called on governments to boost efforts to ensure everyone can access basic healthcare. |
| You are subscribed to email updates from Reuters: Health News. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
Lexo edhe:
